Literature DB >> 8048609

Preischemic glycogen reduction or glycolytic inhibition improves postischemic recovery of hypertrophied rat hearts.

M F Allard1, P G Emanuel, J A Russell, S P Bishop, S B Digerness, P G Anderson.   

Abstract

The purpose of this study was to determine whether metabolites produced by glycolysis during ischemia significantly contribute to myocardial injury of hypertrophied hearts. The accumulation of glycolytic metabolites during ischemia was reduced by means of glycogen reduction or by treatment with the glycolytic inhibitor, 2-deoxy-D-glucose (2-DG) before ischemia. Hearts from aortic-banded (Band) and sham-operated (Sham) rats (8 wk postop) were isolated, perfused with Krebs buffer, and had a left ventricular (LV) balloon to measure developed pressure. A 15-min perfusion with hypoxic buffer (glycogen reduction, GR) or a 10-min perfusion with 10 mM 2-DG (glycolytic inhibition) was followed by 25 min global, normothermic, no-flow ischemia and 30 min normoxic reperfusion. Heart weights were greater in Band than Sham [2.76 +/- 0.06 vs. 1.5 +/- 0.04 (mean +/- SE) g; P < 0.001]. GR and 2-DG each resulted in reduced ATP levels measured at the beginning of ischemia in both Band and Sham groups compared with untreated groups, but there were no differences among groups after 25 min of ischemia. Myocardial lactate levels at the end of ischemia were significantly reduced in both Band and Sham hearts with GR or 2-DG compared with untreated controls. Recovery of LV function after ischemia and reperfusion was significantly improved in Band after GR (206% increase) and after 2-DG treatment (126% increase) compared with their respective untreated controls. Diastolic dysfunction during reperfusion was ameliorated in Band by preischemic GR but not by 2-DG treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8048609     DOI: 10.1152/ajpheart.1994.267.1.H66

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series).

Authors:  Sowndramalingam Sankaralingam; Gary D Lopaschuk
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 2.  Energy metabolism in the hypertrophied heart.

Authors:  Nandakumar Sambandam; Gary D Lopaschuk; Roger W Brownsey; Michael F Allard
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

3.  Role of high-energy phosphate metabolism in hydrogen peroxide-induced cardiac dysfunction.

Authors:  Y Matsumoto; M Kaneko; M Iimuro; Y Fujise; H Hayashi
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

4.  Ischemic preconditioning in rat heart: no correlation between glycogen content and return of function.

Authors:  T Doenst; P H Guthrie; H Taegtmeyer
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

Review 5.  Glucose and glycogen utilisation in myocardial ischemia--changes in metabolism and consequences for the myocyte.

Authors:  L M King; L H Opie
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

6.  The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease.

Authors:  Teresa Coll; Emma Barroso; David Alvarez-Guardia; Lucía Serrano; Laia Salvadó; Manuel Merlos; Xavier Palomer; Manuel Vázquez-Carrera
Journal:  PPAR Res       Date:  2010-07-27       Impact factor: 4.964

7.  In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance.

Authors:  Marie A Schroeder; Lowri E Cochlin; Lisa C Heather; Kieran Clarke; George K Radda; Damian J Tyler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

8.  Transition from metabolic adaptation to maladaptation of the heart in obesity: role of apelin.

Authors:  C Alfarano; C Foussal; O Lairez; D Calise; C Attané; R Anesia; D Daviaud; E Wanecq; A Parini; P Valet; O Kunduzova
Journal:  Int J Obes (Lond)       Date:  2014-07-16       Impact factor: 5.095

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.